Jaguar Health Converts Series O Preferred Stock to Common Shares, Amends Supply Agreement
JAGX sits 23% above its 52-week low of $2.12.
Summary
Jaguar Health announced the conversion of its Series O Preferred Stock into common shares, a dilutive event for common stockholders, alongside a minor amendment to a manufacturing agreement.
Key Events · Financing and Capital Events · JAGX
-
Preferred Stock Conversion
Jaguar Health is converting all outstanding Series O Convertible Preferred Stock into common shares at a ratio of 3.209 common shares per preferred share, effective June 25, 2026. This conversion increases the common share count and is dilutive to existing common stockholders. The Series O Preferred Stock was originally issued as a one-time special stock dividend.
-
Manufacturing Agreement Amendment
Napo Pharmaceuticals, a wholly-owned subsidiary, amended its manufacturing and supply agreement with Woodward Specialty LLC. The amendment clarifies inventory transfer and management responsibilities, primarily due to Woodward's current lack of an Ohio license, ensuring business continuity. This is a minor operational adjustment.
Analysis · JAGX · Life Sciences
Jaguar Health is converting all outstanding Series O Convertible Preferred Stock into common shares. This action, while a pre-planned conversion of a previously issued stock dividend, will increase the number of common shares outstanding, leading to dilution for existing common stockholders. The company also filed a minor amendment to a manufacturing and supply agreement to address logistical issues with a partner.
How filings like this one have moved
In the 30 days to Oct 27, 2026, 29.9% of the 1374 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.12%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, JAGX was trading at $2.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.6M. The 52-week trading range was $2.12 to $115.50. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.